Highly Variable Drug BE Justification [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2017-03-20 07:55 (3025 d 19:31 ago) – Posting: # 17167
Views: 24,867

Hi jag009,

❝ What if one conducted pilot studies and found that the ISCV is like 28/29%? My concensus still would be to proceed with RSABE approach since the it is a mixed approach which allows both RSABE(if Ref SD<0.294) and ABE analysis(if Ref SD>0.294)


That's valid, but if you are not really sure if you are just "borderline" then the additional overhead associated with the replicated design may not be worth it. You find an intra-CVR of 31%, and you scale the limits a wee bit etc. But the price you paid for this moderate scaling option could be much higher than you'd be paying for a conventional 222BE trial with a few extra volunteers. Would be interesting to discuss an objective function here :-)

This isn' the answer, but just a view.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,675 registered users;
43 visitors (0 registered, 43 guests [including 10 identified bots]).
Forum time: 04:26 CEST (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5